Compare LCNB & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LCNB | ELTX |
|---|---|---|
| Founded | 1877 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.1M | 185.4M |
| IPO Year | 1999 | 2014 |
| Metric | LCNB | ELTX |
|---|---|---|
| Price | $17.79 | $3.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 36.1K | ★ 4.5M |
| Earning Date | 04-22-2026 | 05-12-2026 |
| Dividend Yield | ★ 5.43% | N/A |
| EPS Growth | ★ 68.04 | 39.29 |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $6,445,000.00 | $2,301,000.00 |
| Revenue This Year | $8.50 | N/A |
| Revenue Next Year | $3.66 | N/A |
| P/E Ratio | $56.87 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.11 | $2.66 |
| 52 Week High | $18.52 | $16.00 |
| Indicator | LCNB | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.56 | 36.07 |
| Support Level | $15.28 | $2.66 |
| Resistance Level | $18.52 | $9.76 |
| Average True Range (ATR) | 0.49 | 0.50 |
| MACD | -0.04 | 0.11 |
| Stochastic Oscillator | 56.46 | 18.77 |
LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections, and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.